A number of these directors are tied up with Sarama Resources. Maybe Sarama would be taking them over. Seems logical, but no mention of Sarama on the ASX release.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling